![]()
|
Report Date : |
17.05.2007 |
IDENTIFICATION DETAILS
|
Name : |
DAR AL DAWA
DEVELOPMENT & INVESTMENT CO |
|
|
|
|
Registered Office : |
Al Nour Complex, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2005 |
|
|
|
|
Date of Incorporation : |
17th August 1975 |
|
|
|
|
Com. Reg. No.: |
94, |
|
|
|
|
Legal Form : |
Public Shareholding Company – PLC |
|
|
|
|
Line of Business : |
Manufacture and marketing of Antibiotics,
chemotherapeutics, antimycotics, dermatologicals, anti-inflammatories and
analgesics, antihemorrhoidals, cardiovasculars, gastrointestinals and
anti-diabetics, Central nerve system
products and respiratory products, vitamins, minerals,
anti-histamines, gonadotrophins and mouth washes |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
US$ 1,000,000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : DAR AL DAWA DEVELOPMENT & INVESTMENT CO
Doing Business As : DAR AL DAWA
Country of Origin :
Legal Form : Public Shareholding Company - PLC
Registration Date : 17th August 1975
Commercial Registration Number :
94,
Issued Capital : JD 20,000,000
Paid up Capital : JD 20,000,000
Total Workforce : 706
Line of Business : Manufacture and marketing of pharmaceuticals and drugs.
Financial Condition : Good
Payments : Prompt
Operating Trend : Steady
COMPANY NAME
DAR AL DAWA
DEVELOPMENT & INVESTMENT CO
DOING BUSINESS AS
DAR AL DAWA
ADDRESS
Building : Al Nour Complex
Street :
Area : Al Rabia Area
PO Box : 9364
Town :
Country :
Telephone : (962-6) 5539175 / 5727132 / 5539176 /
5539414
Facsimile : (962-6) 5601568 / 5727776 / 5533199
Email : dad@mail.go.com.jo
Premises
Subject operates from
a large suite of offices that are owned and located in the Suburban Business
Area of Amman.
Branch Office (s)
Location Description
·
Nawar
Area Owned
factory premises
Tel : (962-6) 5727132
Fax : (962-6) 5727776
KEY PRINCIPALS
·
Nizar
Abdul Raheem Jardaneh Chairman
·
Dr Sami
Farah Al Halabi Vice
Chairman
·
Mohamed
Sadeq Al Fityani Managing
Director
·
Nabbeh
Al Nabulsi Director
·
Samih
Matalqa Director
·
Mohamed
Yaish Director
·
Issa
Qubain Director
·
Mohamed
Al Sabbagh Director
·
Azmi
Lattouf Director
·
Dr
Abdel Rahman Toukan Director
·
Mohamed
Sameh Qamhawi Director
·
Raouf
Salfiti Director
·
Rashid
A. Dawoodi Director
·
Adnan
Fraij Sales
Manager
·
Khaldoun
Shahati Marketing
Manager
·
Ali M
Ghanayem Finance
Manager
·
Zaki
Abu Ghazaleh Production
Manager
LEGAL FORM &
OWNERS
Date of Establishment : 17th
August 1975
Legal Form :
Sharikat Al Mousahama Al
Aamah (Public Shareholding Company
- PLC)
Commercial Reg. No. : 94,
Issued Capital : JD 20,000,000
Paid up Capital : JD 20,000,000
Name of Shareholder
(s)
·
Nizar
A. Jardaneh
·
Sami Al
Halabi
·
Mohamed
Al Fityani
·
Nabbeh
Al Nabulsi
·
Samih
Matalqa
·
Mohamed
Yaish
·
Issa
Qubain
·
Mohamed
Al Sabbagh
·
Azmi
Lattouf
·
Dr.
Abdel Rahman Toukan
·
Mohamed
Sameh Qamhawi
·
Raouf
Salfiti
·
Rashid
A. Dawoodi
Note to the Legal Form
A Public Shareholding Company (PLC) is formed by two or more shareholders. The liability of the shareholders is limited to their shares in the company’s capital. The minimum authorised capital is set at JD 500,000 of which at least 25 % should be paid upon incorporation, with the remaining 75 % to be paid within four years. Shares must be offered to the public and are freely transferable.
AFFILIATED COMPANIES
Company Percentage
Held
·
Dar Al
Dawa Veterinary & Agricultural Industrial Company Ltd 33.63%
Sahab Industrial Estate
PO Box : 285
Tel : (962-6) 4722559 / 5727981 / 5727982
Fax : (962-6) 4722579 / 5727984
·
Dar
Foodstuffs Company Limited -
PO Box : 285
·
Al
Shifa Co for Medical Industries -
Sana’a
·
Nutri
Food (NUTRIDAR) -
·
Cosmo
Dar -
LINE OF BUSINESS
Operations : Subject is engaged in the manufacture and
marketing of the following products :
- Antibiotics, chemotherapeutics, antimycotics,
dermatologicals, anti-inflammatories and analgesics, antihemorrhoidals, cardiovasculars, gastrointestinals and
anti-diabetics.
- Central nerve system products
- Ophthalmologicals / otologicals / nasals
- Respiratory products,
vitamins, minerals, anti-histamines, gonadotrophins and mouth washes.
Subject holds a manufacturing licence from Parke Davis for 10 of its products.
Import Countries
:
Export Countries
:
Operating Trend
: Steady
Subject has a
workforce of approximately 706 employees.
FINANCIAL HIGHLIGHTS
Financial
highlights provided by outside sources are given below :
Currency :
31/12/03 31/12/04 31/12/05
|
Cash on Hand
& At Bank |
14,076,335 |
14,245,364 |
10,872,895 |
|
Receivables |
26,657,032 |
28,000,771 |
32,383,113 |
|
Stock on Hand |
7,907,371 |
9,817,042 |
9,508,565 |
|
Cheques Under
Collection |
2,241,949 |
2,223,547 |
2,547,137 |
|
Other Current
Assets |
958,010 |
1,082,612 |
1,202,629 |
|
Total Current
Assets |
51,840,698 |
55,369,336 |
56,514,339 |
|
Fixed Assets,
Net |
8,918,233 |
9,083,366 |
9,405,938 |
|
Other Assets |
8,206,360 |
10,204,606 |
25,588,839 |
|
Total Assets |
68,965,291 |
74,657,308 |
82,103,037 |
|
|
|
|
|
|
B- Liabilities |
|
|
|
|
Payables |
4,888,237 |
4,817,049 |
4,805,654 |
|
Other Current
Liabilities |
4,314,391 |
5,571,715 |
8,350,011 |
|
Total Current
Liabilities |
9,202,629 |
10,388,764 |
13,155,665 |
|
Total Liabilities
and Shareholders' Equity |
68,965,291 |
74,657,308 |
82,103,037 |
|
|
|
|
|
|
C - Capital and Shareholders' Equity |
|
|
|
|
Authorized &
Subscribed and Paid-up Capital |
28,248,588 |
28,248,588 |
28,248,588 |
|
Compulsory
Reserves |
9,174,477 |
10,258,119 |
11,425,129 |
|
Voluntary
Reserves |
5,427,350 |
7,594,633 |
9,928,654 |
|
Other Reserves |
8,918,042 |
10,001,684 |
11,168,695 |
|
Proposed
Dividends |
5,649,718 |
5,649,718 |
5,649,718 |
|
Retained Earnings |
2,344,487 |
1,950,832 |
2,526,589 |
|
Shareholders'
Equity |
59,762,662 |
64,268,544 |
68,947,371 |
|
|
|
|
|
|
Profit & Loss
Statement |
|
|
|
|
Net Sales |
39,378,229 |
40,551,552 |
46,384,401 |
|
Cost of Sales |
-18,142,356 |
-17,478,891 |
-20,974,883 |
|
Gross Profit |
21,235,873 |
23,072,661 |
25,409,518 |
|
Administrative,
General and other Expenses |
-11,417,178 |
-12,340,234 |
15,540,435 |
|
Other Revenues |
649,004 |
810,196 |
1,801,021 |
|
Net Income before
allocations |
9,761,484 |
10,836,408 |
11,671,517 |
|
Board of Directors'
remuneration |
-70,621 |
-70,621 |
77,684 |
|
Income Tax |
-313,510 |
-334,661 |
401,771 |
|
Other
Expenditures |
-243,575 |
-275,527 |
297,134 |
|
Net Profit |
9,133,778 |
10,155,599 |
10,893,517 |
Local sources consider
subject’s financial condition to be Good.
BANKERS
·
Arab
Bank Plc
PO Box : 8 & 68
Tel : (962-6) 5638161
Fax : (962-6) 5637082
·
Jordan
Kuwait Bank
Abdali Branch
PO Box : 9776
Tel : (962-6) 5688814
·
HSBC
Bank
Jebel Hussein
PO Box : 925286
Tel : (962-6) 5660471 / 5607471
Fax : (962-6) 5692964
·
Jordan
National Bank
PO Box : 1578
Tel : (962-6) 4612391
PAYMENT HISTORY
Subject’s payment
record is reported to be met in a generally prompt manner.
GENERAL COMMENTS
Dar Al Dawa
Development & Investment Co is a leading concern in its field in
Local sources
report that subject’s financial position is deemed satisfactory and that
payments are generally made in a prompt manner.
Maximum suggested
credit figure: US$ 1,000,000
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)